Top

Published in:

Open Access 01-12-2018 | Research article

ENHO, RXRA, and LXRA polymorphisms and dyslipidaemia, related comorbidities and survival in haemodialysis patients

Authors: Alicja E. Grzegorzewska, Leszek Niepolski, Monika K. Świderska, Adrianna Mostowska, Ireneusz Stolarek, Wojciech Warchoł, Marek Figlerowicz, Paweł P. Jagodziński

Published in: BMC Medical Genetics | Issue 1/2018

Abstract

Background

The energy homeostasis-associated gene (ENHO), retinoid X receptor alpha gene (RXRA), and liver X receptor alpha gene (LXRA) are involved in adipogenic/lipogenic regulation. We investigated whether single-nucleotide polymorphisms in these genes (ENHO rs2281997, rs72735260; RXRA rs749759, rs10776909, rs10881578; LXRA rs2279238, rs7120118, rs11039155) are associated with dyslipidaemia, related comorbidities and survival of haemodialysis (HD) patients also tested for T-helper (Th) cell interleukin genes (IL).

Methods

The study was carried out in 873 HD patients. Dyslipidaemia was diagnosed by the recommendations of the Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines (2003); atherogenic dyslipidaemia was referred to if the TG/HDL cholesterol ratio was equal to or higher than 3.8. Genotyping of ENHO SNPs, LXRA SNPs, and IL12A rs568408 was carried out using HRM analysis. RXRA SNPs, IL12B rs3212227, and IL18 rs360719 were genotyped using PCR-RFLP analysis. The circulating adropin concentration was determined in 126 patients by enzyme-linked immunosorbent assay. Survival probability was analysed using the Kaplan-Meier method in 440 patients followed through 7.5 years.

Results

Dyslipidaemia by K/DOQI was diagnosed in 459 patients (91% revealed hyper-LDL- cholesterolaemia), atherogenic dyslipidaemia was diagnosed in 454 patients, and 231 patients were free of dyslipidaemia by both criteria. The variant allele (T) of ENHO rs2281997 was associated with the hyper-LDL cholesterolaemic pattern of dyslipidaemia by K/DOQI. The frequency of atherogenic dyslipidaemia was lower in T-allele bearers than in CC-genotype patients. The rs2281997 T allele was associated with lower cardiovascular mortality in HD patients showing atherogenic dyslipidaemia. ENHO, RXRA, and LXRA showed epistatic interactions in dyslipidaemia. Circulating adropin was lower in atherogenic dyslipidaemia than in non-atherogenic conditions. RXRA rs10776909 was associated with myocardial infarction. Bearers of LXRA rs2279238, rs7120118 or rs11039155 minor alleles showed higher mortality. ENHO SNP positions fell within the same DNase 1 hypersensitivity site expressed in the Th1 cell line. Epistatic interactions occurred between rs2281997 and Th1 IL SNPs (rs360719, rs568408).

Conclusions

Atherogenic dyslipidaemia occurs in HD patients in whom ENHO encodes less adropin. ENHO, RXRA, and LXRA SNPs, separately or jointly, are associated with dyslipidaemia, myocardial infarction, and survival in HD patients. Differences in the availability of transcription binding sites may contribute to these associations.

Available only for authorised users

Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495–506. https://doi.org/10.1161/01.cir.82.2.495.CrossRefPubMed

Hanak V, Munoz J, Teague J, Stanley A, Bittner V. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. Am J Cardiol. 2004;94:219–22. https://doi.org/10.1016/j.amjcard.2004.03.069.CrossRefPubMed

Kohli A, Siddhu A, Pandey RM, Reddy KS. Relevance of the triglyceride-to-high-density lipoprotein cholesterol ratio as an important lipid fraction in apparently healthy, young, and middle-aged Indian men. Indian J Endocr Metab. 2017;21:113–8.CrossRef

Flowers E, Molina C, Mathur A, Reaven GM. Use of plasma triglyceride/high-density lipoprotein cholesterol ratio to identify increased cardio-metabolic risk in young, healthy south Asians. Indian J Med Res. 2015;141:68–74.CrossRefPubMedPubMedCentral

Edwards MK, Blaha MJ, Loprinzi PD. Atherogenic index of plasma and triglyceride/high-density lipoprotein cholesterol ratio predict mortality risk better than individual cholesterol risk factors, among an older adult population. Mayo Clin Proc. 2017;92:680–1. https://doi.org/10.1016/j.mayocp.2016.12.018.CrossRefPubMed

Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ. Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int. 2003;84:Suppl S121–4.CrossRef

Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int. 1996;50:1928–35.CrossRefPubMed

Cheung AK, Parker CJ, Ren K, Iverius PH. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int. 1996;49:1360–71.CrossRefPubMed

Charlesworth JA, Kriketos AD, Jones JE, Erlich JH, Campbell LV, Peake PW. Insulin resistance and postprandial triglyceride levels in primary renal disease. Metabolism. 2005;54:821–8.CrossRefPubMed

10.

Mordasini R, Frey F, Flury W, Klose G, Greten H. Selective deficiency of hepatic triglyceride lipase in uremic patients. N Engl J Med. 1977;297:1362–6.CrossRefPubMed

11.

Calabresi L, Simonelli S, Conca P, Busnach G, Cabibbe M, Gesualdo L, et al. Acquired lecithin:cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease. J Intern Med. 2015;277:552–61. https://doi.org/10.1111/joim.12290.CrossRefPubMed

12.

Kaysen GA. Disorders in high-density metabolism with insulin resistance and chronic kidney disease. J Ren Nutr. 2007;17:4–8.CrossRefPubMed

13.

Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000;35:852–62.CrossRefPubMed

14.

Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003;41(4 Suppl 3):I–IV S1-S91.

15.

Lee MJ, Park JT, Han SH, Kim YL, Kim YS, Yang CW, et al. The atherogenic index of plasma and the risk of mortality in incident dialysis patients: Results from a nationwide prospective cohort in Korea. PLoS One. 2017;12(5):e0177499. https://doi.org/10.1371/journal.pone.0177499 PMID: 28549070.CrossRefPubMedPubMedCentral

16.

Chen HY, Tsai WC, Chiu YL, Hsu SP, Pai MF, Yang JY, et al. Triglyceride to High-Density Lipoprotein Cholesterol Ratio Predicts Cardiovascular Outcomes in Prevalent Dialysis Patients. Medicine (Baltimore). 2015;94:e619. https://doi.org/10.1097/MD.0000000000000619.CrossRef

17.

Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of Adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8:468–81. https://doi.org/10.1016/j.cmet.2008.10.011.CrossRefPubMedPubMedCentral

18.

Cammas L, Reinaud P, Bordas N, Dubois O, Germain G, Charpigny G. Developmental regulation of prostacyclin synthase and prostacyclin receptors in the ovine uterus and conceptus during the peri-implantation period. Reproduction. 2006;131:917–27. https://doi.org/10.1530/rep.1.00799.CrossRefPubMed

19.

Kalaany NY, Mangelsdorf DJ. LXRS AND FXR: The yin and Yang of cholesterol and fat metabolism. Annu Rev Physiol. 2006;68:159–91. https://doi.org/10.1146/annurev.physiol.68.033104.152158.CrossRefPubMed

20.

Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 1995;9:1033–45. https://doi.org/10.1101/gad.9.9.1033.CrossRefPubMed

21.

Yolbas S, Kara M, Yilmaz M, Aydin S, Koca SS. Serum adropin level and ENHO gene expression in systemic sclerosis. Clin Rheumatol. 2016;35:1535–40. https://doi.org/10.1007/s10067-016-3266-1.CrossRefPubMed

22.

Grzegorzewska AE, Niepolski L, Mostowska A, Warchoł W, Jagodziński PP. Involvement of adropin and adropin-associated genes in metabolic abnormalities of hemodialysis patients. Life Sci. 2016;160:41–6. https://doi.org/10.1016/j.lfs.2016.07.009.CrossRefPubMed

23.

Legry V, Bokor S, Beghin L, Galfo M, Gonzalez-Gross M, Molnar D, et al. HELENA study group. Associations between common genetic polymorphisms in the liver X receptor alpha and its target genes with the serum HDL cholesterol concentration in adolescents of the HELENA study. Atherosclerosis. 2011;216:166–9. https://doi.org/10.1016/j.atherosclerosis.2011.01.031.CrossRefPubMed

24.

Smith AJ, Howard P, Shah S, Eriksson P, Stender S, Giambartolomei C, et al. Use of allele-specific FAIRE to determine functional regulatory polymorphism using large-scale genotyping arrays. PLoS Genet. 2012;8:e1002908. https://doi.org/10.1371/journal.pgen.1002908.CrossRefPubMedPubMedCentral

25.

Sabatti C, Service SK, Hartikainen AL, Pouta A, Ripatti S, Brodsky J, et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet. 2009;41:35–46. https://doi.org/10.1038/ng.271.CrossRefPubMed

26.

Butler AA, Tam CS, Stanhope KL, Wolfe BM, Ali MR, O'keeffe M, et al. Low circulating Adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab. 2012;97:3783–91. https://doi.org/10.1210/jc.2012-2194.CrossRefPubMedPubMedCentral

27.

Yu H-Y, Zhao P, Wu M-C, Liu J, Yin W. Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept. 2014;190–1:46–9. https://doi.org/10.1016/j.regpep.2014.04.001.CrossRef

28.

Zhang C, Zhao L, Xu W, Li J, Wang B, Gu X, et al. Correlation of serum adropin level with coronary artery disease. Zhonghua Yi Xue Za Zhi. 2014;94:1255–7.PubMed

29.

Oshchepkov DY, Levitsky VG. In silico prediction of transcriptional factor-binding sites. Methods Mol Biol. 2011;760:251–67. https://doi.org/10.1007/978-1-61779-176-5_16 PMID: 21780002.CrossRefPubMed

30.

Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol. 2000;164:1364–71 PMID: 10640751.CrossRefPubMed

31.

Smart MC, Dedoussis G, Yiannakouris N, Grisoni ML, Dror GK, Yannakoulia M, et al. Genetic variation within IL18 is associated with insulin levels, insulin resistance and postprandial measures. Nutr Metab Cardiovasc Dis. 2011;21:476–84. https://doi.org/10.1016/j.numecd.2009.12.004 PMID: 20227263.CrossRefPubMedPubMedCentral

32.

Yamanishi K, Maeda S, Kuwahara-Otani S, Watanabe Y, Yoshida M, Ikubo K, et al. Interleukin-18-deficient mice develop dyslipidemia resulting in nonalcoholic fatty liver disease and steatohepatitis. Transl Res. 2016;173:101–14.e7. https://doi.org/10.1016/j.trsl.2016.03.010 PMID:27063959.CrossRefPubMed

33.

Salisbury D, Bronas U. Inflammation and immune system contribution to the etiology of atherosclerosis: mechanisms and methods of assessment. Nurs Res. 2014;63:375–85. https://doi.org/10.1097/NNR.0000000000000053 PMID:25171563.CrossRefPubMed

34.

Disease K. Improving Global Outcomes (KDIGO) Lipid Work Group KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. 2013;3 Suppl:259–305.

35.

Grzegorzewska AE, Świderska MK, Warchoł W. Antibodies to hepatitis B virus surface antigen and survival of hemodialysis patients - a prospective study. Expert Rev Vaccines. 2016;15:1063–74. https://doi.org/10.1080/14760584.2016.1188697.CrossRefPubMed

36.

Grzegorzewska AE, Świderska MK, Mostowska A, Warchoł W, Jagodziński PP. Polymorphisms of Vitamin D Signaling Pathway Genes and Calcium-Sensing Receptor Gene in respect to Survival of Hemodialysis Patients: A Prospective Observational Study. Int J Endocrinol. 2016;2016:2383216. https://doi.org/10.1155/2016/2383216.CrossRefPubMedPubMedCentral

37.

Świderska M, Mostowska A, Grzegorzewska AE. T helper cell-related cytokine gene polymorphisms and vitamin D pathway gene polymorphisms as predictors of survival probability in patients on renal replacement therapy. Pol Arch Med Wewn. 2015;125:511–20.PubMed

38.

Rosenbloom KR, Sloan CA, Malladi VS, Dreszer TR, Learned K, Kirkup VM, et al. ENCODE data in the UCSC genome browser: year 5 update. Nucleic Acids Res. 2013;41:D56–63. https://doi.org/10.1093/nar/gks1172.CrossRefPubMed

39.

Kulakovskiy IV, Vorontsov IE, Yevshin IS, Soboleva AV, Kasianov AS, Ashoor H, et al. HOCOMOCO: expansion and enhancement of the collection of transcription factor binding sites models. Nucleic Acids Res. 2016;44:D116–25. https://doi.org/10.1093/nar/gkv1249.CrossRefPubMed

40.

Mathelier A, Fornes O, Arenillas DJ, Chen C-Y, Denay G, Lee J, et al. JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2016;44:D110–5. https://doi.org/10.1093/nar/gkv1176.CrossRefPubMed

41.

Weirauch MT, Yang A, Albu M, Cote AG, Montenegro-Montero A, Drewe P, et al. Determination and inference of eukaryotic transcription factor sequence specificity. Cell. 2014;158:1431–43. https://doi.org/10.1016/j.cell.2014.08.009.CrossRefPubMedPubMedCentral

42.

Grant CE, Bailey TL, Noble WS. FIMO: scanning for occurrences of a given motif. Bioinformatics. 2011;27:1017–8. https://doi.org/10.1093/bioinformatics/btr064.CrossRefPubMedPubMedCentral

43.

Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL. GenBank. Nucleic Acids Res. 2005;33:D34–8. https://doi.org/10.1093/nar/gki063.CrossRefPubMed

44.

Grzegorzewska AE, Paciorkowski M, Mostowska A, Frycz B, Warchoł W, Stolarek I, et al. Associations of the calcium-sensing receptor gene CASR rs7652589 SNP with nephrolithiasis and secondary hyperparathyroidism in haemodialysis patients. Sci Rep. 2016;6:35188. https://doi.org/10.1038/srep35188.CrossRefPubMedPubMedCentral

45.

Gauderman WJ, Morrison JM. QUANTO 1.2.4: a computer program for power and sample size calculations for genetic–epidemiology studies. University of Southern California: Los Angeles, CA, 2009. Available from: http://biostats.usc.edu/Quanto.html. Accessed 15 June 2017.

46.

Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics. 2003;19:376–82. https://doi.org/10.1093/bioinformatics/btf869.CrossRefPubMed

47.

Manly KF. Reliability of statistical associations between genes and disease. Immunogenetics. 2005;57:549–58. https://doi.org/10.1007/s00251-005-0025-x.CrossRefPubMed

48.

Hu W, Chen L. Association of Serum Adropin Concentrations with diabetic nephropathy. Mediat Inflamm. 2016;2016:6038261. https://doi.org/10.1155/2016/6038261.CrossRef

49.

Kumar KG, Zhang J, Gao S, Rossi J, Mcguinness OP, Halem HH, et al. Adropin Deficiency Is Associated With Increased Adiposity and Insulin Resistance. Obesity (Silver Spring). 2012;20:1394–402. https://doi.org/10.1038/oby.2012.31.CrossRef

50.

Rodriguez-Jato S, Nicholls RD, Driscoll DJ, Yang TP. Characterization of cis- and trans-acting elements in the imprinted human SNURF-SNRPN locus. Nucleic Acids Res. 2005;33:4740–53. https://doi.org/10.1093/nar/gki786.CrossRefPubMedPubMedCentral

51.

Aribi M, Moulessehoul S, Kendouci-Tani M, Benabadji AB, Hichami A, Khan NA. Relationship between interleukin-1beta and lipids in type 1 diabetic patients. Med Sci Monit. 2007;13:CR372–8.PubMed

52.

Tso TK, Huang WN, Huang HY, Chang CK. Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2006;45:1148–53. https://doi.org/10.1093/rheumatology/kel082.CrossRefPubMed

53.

Nikołajuk A, Karczewska-Kupczewska M, Straczkowski M. Relationship between serum IL-12 and p40 subunit concentrations and lipid parameters in overweight and obese women. Metab Syndr Relat Disord. 2015;13:336–42. https://doi.org/10.1089/met.2014.0164.CrossRefPubMed

54.

Gluba-Brzózka A, Franczyk B, Banach M, Rysz-Górzyńska M. Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients? Int Urol Nephrol. 2017;49:155–64. https://doi.org/10.1007/s11255-016-1466-x.CrossRefPubMed

55.

Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007;18:293–303. https://doi.org/10.1681/ASN.2006070795.CrossRefPubMed

56.

Cofan F, Vela E, Clèries M. Collaborative Study Group for Dyslipidemia. Analysis of dyslipidemia in patients on chronic hemodialysis in Catalonia. Atherosclerosis. 2006;184:94–102. https://doi.org/10.1016/j.atherosclerosis.2005.03.021.CrossRefPubMed

57.

Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–82 PMID:2333868.CrossRefPubMed

58.

Yoshihisa A, Kanno Y, Watanabe S, Yokokawa T, Abe S, Miyata M, et al. Impact of nutritional indices on mortality in patients with heart failure. Open Heart. 2018;5:e000730. https://doi.org/10.1136/openhrt-2017-000730.CrossRefPubMedPubMedCentral

59.

Bonanni A, Mannucci I, Verzola D, Sofia A, Saffioti S, Gianetta E, et al. Protein-energy wasting and mortality in chronic kidney disease. Int J Environ Res Public Health. 2011;8:1631–54. https://doi.org/10.3390/ijerph8051631 PMID:21655142.CrossRefPubMedPubMedCentral

60.

Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. Genes Dev. 2000;14:2831–8 PMID: 11090131.CrossRefPubMedPubMedCentral

61.

Price ET, Pacanowski MA, Martin MA, Cooper-Dehoff RM, Pepine CJ, Zineh I, et al. Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy. Pharmacogenet Genomics. 2011;21:333–40. https://doi.org/10.1097/fpc.0b013e3283452fec.CrossRefPubMedPubMedCentral

62.

Hsu L-S, Wu P-R, Yeh K-T, Yeh C-M, Shen K-H, Chen C-J, et al. Positive nuclear expression of KLF8 might be correlated with shorter survival in gastric adenocarcinoma. Ann Diagn Pathol. 2014;18:74–7. https://doi.org/10.1016/j.anndiagpath.2013.12.001.CrossRefPubMed

63.

Kienreich K, Tomaschitz A, Verheyen N, Pieber T, Gaksch M, Grübler MR, et al. Vitamin D and cardiovascular disease. Nutrients. 2013;5:3005–21. https://doi.org/10.3390/nu5083005.CrossRefPubMedPubMedCentral

64.

Wolf AT, Medcalf RL, Jern C. The t-PA -7351C>T enhancer polymorphism decreases Sp1 and Sp3 protein binding affinity and transcriptional responsiveness to retinoic acid. Blood. 2005;105:1060–7. https://doi.org/10.1182/blood-2003-12-4383.CrossRefPubMed

Title: ENHO, RXRA, and LXRA polymorphisms and dyslipidaemia, related comorbidities and survival in haemodialysis patients
Authors: Alicja E. Grzegorzewska
Leszek Niepolski
Monika K. Świderska
Adrianna Mostowska
Ireneusz Stolarek
Wojciech Warchoł
Marek Figlerowicz
Paweł P. Jagodziński
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Medical Genetics / Issue 1/2018
Electronic ISSN: 1471-2350
DOI: https://doi.org/10.1186/s12881-018-0708-4

At a glance: The STEP trials

Springer Medicine

ENHO, RXRA, and LXRA polymorphisms and dyslipidaemia, related comorbidities and survival in haemodialysis patients

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

MiR-146a G/C rs2910164 variation in South African Indian and Caucasian patients with psoriatic arthritis

Muscle-specific regulation of right ventricular transcriptional responses to chronic hypoxia-induced hypertrophy by the muscle ring finger-1 (MuRF1) ubiquitin ligase in mice

Do polymorphisms in protein kinase catalytic subunit alpha-1 gene associated with cancer susceptibility? a meta-analysis and systematic review

Establishing a genetic link between FTO and VDR gene polymorphisms and obesity in the Emirati population

Possible association between ABCC8 C49620T polymorphism and type 2 diabetes in a Nigerian population

Novel digenic inheritance of PCDH15 and USH1G underlies profound non-syndromic hearing impairment